Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Core Viewpoint - Q32 Bio reported a significant turnaround in financial performance for Q4 2025, achieving a net income of $57.7 million, driven by collaboration revenue and the sale of ADX-097, while focusing on advancing bempikibart for alopecia areata [1][2]. Financial Results - Net income for Q4 2025 was $57.7 million, translating to $4.60 per basic share and $4.58 per diluted share, compared to a net loss of $14.2 million in Q4 2024 [2][3]. - For the full year 2025, net income was $29.8 million, or $2.42 per share, compared to a net loss of $47.7 million in 2024 [2][3]. - General and administrative expenses were $4.5 million for Q4 2025, up from $4.0 million in Q4 2024, while full-year expenses decreased to $17.7 million from $18.0 million [2]. - Research and development expenses significantly decreased to $3.3 million for Q4 2025 from $10.5 million in Q4 2024, and for the full year, they dropped to $19.2 million from $48.1 million [2]. Corporate Updates - Q32 Bio completed a $10.5 million registered direct offering in February 2026, issuing 1,666,679 shares at $3.90 each [1][2]. - The company sold the Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million upfront, with potential total payments of up to $592 million based on future milestones [1][2]. - Enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial was completed, increasing the trial size to 33 patients, with topline data expected in mid-2026 [1][2]. Clinical Development - Bempikibart, a fully human anti-IL-7R antibody, is being evaluated in the SIGNAL-AA Phase 2a clinical trial for alopecia areata, with promising pharmacokinetic data suggesting earlier responsiveness [1][2]. - The trial aims to assess efficacy based on changes in Severity of Alopecia Tool (SALT) scores, with follow-up extending to 52 weeks [1][2].